You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAfatinib
Accession NumberDB08916
TypeSmall Molecule
GroupsApproved
DescriptionAfatinib is a tyrosine kinase inhibitor which is a 4-anilinoquinazoline. It is prepared has the dimaleate salt. FDA approved on July 12, 2013.
Structure
Thumb
Synonyms
Afatinibum
BIBW 2992
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GilotrifTablet, film coated40 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2013-07-12Not applicableUs
GilotrifTablet, film coated20 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2013-07-12Not applicableUs
GilotrifTablet, film coated30 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2013-07-12Not applicableUs
GiotrifTablet20 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2014-01-17Not applicableCanada
GiotrifTablet30 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2014-01-17Not applicableCanada
GiotrifTablet40 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2014-01-17Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Afatinib Dimaleate
850140-73-7
Thumb
  • InChI Key: USNRYVNRPYXCSP-JUGPPOIOSA-N
  • Monoisotopic Mass: 717.184912835
  • Average Mass: 718.083
DBSALT000005
Categories
UNII41UD74L59M
CAS number850140-72-6
WeightAverage: 485.938
Monoisotopic: 485.162995603
Chemical FormulaC24H25ClFN5O3
InChI KeyULXXDDBFHOBEHA-CWDCEQMOSA-N
InChI
InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
IUPAC Name
(2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
SMILES
CN(C)C\C=C\C(=O)NC1=C(O[[email protected]]2CCOC2)C=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=C1
Pharmacology
IndicationAfatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Structured Indications
PharmacodynamicsAfatinib did not effect the QTc interval.
Mechanism of actionAfatinib is an irreversible kinase inhibitor and binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) to inhibit tyrosine kinase autophosphorylation. This results in a downregulation of ErbB signalling and subsequent inhibition of proliferation of cell lines expressing wild-type EGFR, selected EGFR exon 19 deletion mutations, or exon 21 L858R mutations. It also inhibited in vitro proliferation of cell lines overexpressing HER2. Overall, tumour growth was inhibited.
TargetKindPharmacological actionActionsOrganismUniProt ID
Epidermal growth factor receptorProteinyes
inhibitor
HumanP00533 details
Receptor tyrosine-protein kinase erbB-2Proteinyes
inhibitor
HumanP04626 details
Receptor tyrosine-protein kinase erbB-4Proteinyes
inhibitor
HumanQ15303 details
Related Articles
AbsorptionFollowing oral administration, time to peak plasma concentration (Tmax) is 2 to 5 hours. The geometric mean relative bioavailability of 20 mg tablets was 92% as compared to an oral solution. Food decreases Cmax and AUC relative to the fasted state.
Volume of distributionNot Available
Protein binding95% bound to human plasma protein.
Metabolism

Enzymatic metabolism of afatinib is minimal. Covalent adducts to proteins are the major circulating metabolites.

Route of eliminationExcretion of afatinib is primarily via the feces (85%), with 4% recovered in the urine following a single oral dose of afatinib solution. The parent compound accounted for 88% of the recovered dose.
Half lifeCancer patients, repeat dosing = 37 hours
ClearanceNot Available
ToxicityMost common adverse reactions (≥20%) are diarrhea, rash/dermatitis, acneiform, stomatitis, paronychia, dry skin, decreased appetite, pruritus.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Epidermal growth factor receptor
Gene symbol: EGFR
UniProt: P00533
Not AvailableG719A/C OR (L858R and L861Q)Not AvailableAssociated with enhanced activation of the EGFR tyrosine kinase in patients with non-small cell lung cancer (NSCLC) recieving tyrosine kinase inhibitor therapy.15118073
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Afatinib.Approved
AcetaminophenThe serum concentration of Afatinib can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Afatinib.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Afatinib.Approved, Vet Approved
AlbendazoleThe serum concentration of Afatinib can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Afatinib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Afatinib can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Afatinib can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Afatinib.Approved, Investigational
AmantadineThe serum concentration of Afatinib can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Afatinib.Approved, Investigational
Aminohippuric acidThe serum concentration of Afatinib can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Afatinib can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Afatinib can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Afatinib can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Afatinib can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Afatinib can be increased when it is combined with Amsacrine.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Afatinib.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Afatinib.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Afatinib.Approved, Investigational
AstemizoleThe serum concentration of Afatinib can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Afatinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Afatinib can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Afatinib can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Afatinib.Approved, Investigational
AzelastineThe serum concentration of Afatinib can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Afatinib can be increased when it is combined with Azithromycin.Approved
BenzocaineThe serum concentration of Afatinib can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Afatinib can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Afatinib.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Afatinib.Approved, Investigational
BiperidenThe serum concentration of Afatinib can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Afatinib.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Afatinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Afatinib.Approved
BromocriptineThe serum concentration of Afatinib can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Afatinib can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Afatinib can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Afatinib can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Afatinib can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Afatinib.Experimental
CanagliflozinThe serum concentration of Afatinib can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Afatinib can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Afatinib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Afatinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Afatinib.Approved
CarvedilolThe serum concentration of Afatinib can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Afatinib can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Afatinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Afatinib.Withdrawn
ChloroquineThe serum concentration of Afatinib can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Afatinib can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Afatinib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Afatinib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Afatinib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Afatinib can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Afatinib can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Afatinib can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Afatinib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Afatinib.Approved
CitalopramThe serum concentration of Afatinib can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Afatinib can be increased when it is combined with Clarithromycin.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Afatinib.Approved, Illicit
ClofazimineThe serum concentration of Afatinib can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Afatinib.Approved, Investigational
ClomipramineThe serum concentration of Afatinib can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Afatinib.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Afatinib.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Afatinib can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Afatinib.Approved
CobicistatThe serum concentration of Afatinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Afatinib.Approved
ColchicineThe serum concentration of Afatinib can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Afatinib can be increased when it is combined with Colforsin.Experimental
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Afatinib.Approved
CrizotinibThe serum concentration of Afatinib can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Afatinib can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Afatinib can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Afatinib.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Afatinib.Approved
DaclatasvirThe serum concentration of Afatinib can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Afatinib can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Afatinib.Approved
DasatinibThe serum concentration of Afatinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Afatinib can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Afatinib.Approved
DesipramineThe serum concentration of Afatinib can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Afatinib.Approved
DesloratadineThe serum concentration of Afatinib can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Afatinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Afatinib can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Afatinib.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Afatinib can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Afatinib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Afatinib.Approved
DigoxinThe serum concentration of Afatinib can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Afatinib can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Afatinib.Illicit
DiltiazemThe serum concentration of Afatinib can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Afatinib can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afatinib.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Afatinib.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Afatinib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Afatinib can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Afatinib.Approved, Investigational
DoxorubicinThe serum concentration of Afatinib can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Afatinib can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Afatinib can be increased when it is combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Afatinib.Approved
ElbasvirThe serum concentration of Afatinib can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Afatinib.Approved, Investigational
EltrombopagThe serum concentration of Afatinib can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Afatinib can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Afatinib can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Afatinib.Approved, Investigational
ErgonovineThe serum concentration of Afatinib can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Afatinib can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Afatinib.Approved, Investigational
ErythromycinThe serum concentration of Afatinib can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Afatinib.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Afatinib can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Afatinib can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Afatinib can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Afatinib.Approved
EtoposideThe serum concentration of Afatinib can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Afatinib can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Afatinib.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Afatinib.Approved
FelodipineThe serum concentration of Afatinib can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Afatinib can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Afatinib.Approved
FexofenadineThe serum concentration of Afatinib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Afatinib can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Afatinib can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Afatinib can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Afatinib can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Afatinib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Afatinib can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Afatinib.Approved
FluvoxamineThe serum concentration of Afatinib can be increased when it is combined with Fluvoxamine.Approved, Investigational
GefitinibThe serum concentration of Afatinib can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Afatinib.Approved
GenisteinThe serum concentration of Afatinib can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Afatinib can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Afatinib can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Afatinib can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Afatinib.Approved
GrepafloxacinThe serum concentration of Afatinib can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Afatinib can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Afatinib can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Afatinib.Approved
IdelalisibThe serum concentration of Afatinib can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Afatinib can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Afatinib can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Afatinib.Approved
IndinavirThe serum concentration of Afatinib can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Afatinib can be increased when it is combined with Indomethacin.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Afatinib.Approved, Investigational
IsavuconazoniumThe serum concentration of Afatinib can be increased when it is combined with Isavuconazonium.Approved, Investigational
ItraconazoleThe serum concentration of Afatinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Afatinib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Afatinib can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Afatinib can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Afatinib.Approved
KetoconazoleThe serum concentration of Afatinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Afatinib.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Afatinib.Approved, Investigational
LansoprazoleThe serum concentration of Afatinib can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Afatinib can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Afatinib.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Afatinib.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Afatinib.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Afatinib.Approved, Investigational
LevofloxacinThe serum concentration of Afatinib can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Afatinib.Approved
LevothyroxineThe serum concentration of Afatinib can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Afatinib can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Afatinib.Approved
LiothyronineThe serum concentration of Afatinib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Afatinib can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Afatinib can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Afatinib can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Afatinib can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Afatinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Afatinib can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Afatinib can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Afatinib can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Afatinib can be decreased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Afatinib.Approved, Investigational
MaprotilineThe serum concentration of Afatinib can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Afatinib can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Afatinib can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Afatinib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Afatinib can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Afatinib can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Afatinib.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Afatinib.Approved, Vet Approved
MetoprololThe serum concentration of Afatinib can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Afatinib can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Afatinib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Afatinib can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Afatinib can be decreased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Afatinib.Approved
MitomycinThe serum concentration of Afatinib can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Afatinib can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Afatinib can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Afatinib.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Afatinib.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Afatinib.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Afatinib.Approved, Vet Approved
NaltrexoneThe serum concentration of Afatinib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Afatinib can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Afatinib can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Afatinib can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Afatinib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Afatinib can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Afatinib can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Afatinib can be increased when it is combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Afatinib.Approved
NisoldipineThe serum concentration of Afatinib can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Afatinib can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Afatinib can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Afatinib.Approved
NorethisteroneThe serum concentration of Afatinib can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Afatinib.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Afatinib.Approved
OmeprazoleThe serum concentration of Afatinib can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Afatinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Afatinib.Approved
P-NitrophenolThe serum concentration of Afatinib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Afatinib can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Afatinib can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Afatinib.Approved, Investigational
PantoprazoleThe serum concentration of Afatinib can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Afatinib can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Afatinib.Approved
PerindoprilThe serum concentration of Afatinib can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Afatinib can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Afatinib.Approved, Vet Approved
PimozideThe serum concentration of Afatinib can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Afatinib.Approved
Platelet Activating FactorThe serum concentration of Afatinib can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Afatinib.Approved
PonatinibThe serum concentration of Afatinib can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Afatinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Afatinib can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Afatinib can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Afatinib.Approved, Vet Approved
PrednisoneThe serum concentration of Afatinib can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Afatinib can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Afatinib can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Afatinib can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Afatinib can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Afatinib can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Afatinib can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Afatinib.Approved
QuercetinThe serum concentration of Afatinib can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Afatinib.Approved
QuinacrineThe serum concentration of Afatinib can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Afatinib can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Afatinib can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Afatinib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Afatinib.Approved, Investigational
ReboxetineThe serum concentration of Afatinib can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Afatinib can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Afatinib can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Afatinib can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Afatinib.Approved, Investigational
RilpivirineThe serum concentration of Afatinib can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Afatinib.Approved, Investigational
RitonavirThe serum concentration of Afatinib can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Afatinib.Approved
RolapitantThe serum concentration of Afatinib can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Afatinib.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Afatinib.Approved, Vet Approved
SaquinavirThe serum concentration of Afatinib can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Afatinib can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Afatinib can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Afatinib.Approved
SertralineThe serum concentration of Afatinib can be increased when it is combined with Sertraline.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Afatinib.Approved
SimeprevirThe serum concentration of Afatinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Afatinib can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Afatinib can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Afatinib.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Afatinib.Approved
SorafenibThe serum concentration of Afatinib can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Afatinib.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Afatinib.Experimental
SpironolactoneThe serum concentration of Afatinib can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Afatinib can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Afatinib can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Afatinib can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Afatinib can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Afatinib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Afatinib can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Afatinib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Afatinib can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Afatinib can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Afatinib can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Afatinib.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Afatinib.Approved
TelmisartanThe serum concentration of Afatinib can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Afatinib can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Afatinib can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Afatinib can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Afatinib can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Afatinib can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Afatinib can be increased when it is combined with Testosterone.Approved, Investigational
TicagrelorThe serum concentration of Afatinib can be increased when it is combined with Ticagrelor.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Afatinib.Approved
TolvaptanThe serum concentration of Afatinib can be increased when it is combined with Tolvaptan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Afatinib.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Afatinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Afatinib.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Afatinib.Approved
TrazodoneThe serum concentration of Afatinib can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Afatinib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Afatinib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Afatinib can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Afatinib can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Afatinib can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Afatinib.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Afatinib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Afatinib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Afatinib.Approved
VenlafaxineThe serum concentration of Afatinib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Afatinib can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Afatinib can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Afatinib.Approved, Investigational
VincristineThe serum concentration of Afatinib can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Afatinib can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Afatinib.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Afatinib.Approved
ZimelidineThe serum concentration of Afatinib can be increased when it is combined with Zimelidine.Withdrawn
Food Interactions
  • When given with a high-fat meal, Cmax decreases by 50% and AUC by 39% relative to the fasted state.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL01XE13
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (427 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8717
Caco-2 permeable-0.5342
P-glycoprotein substrateSubstrate0.744
P-glycoprotein inhibitor IInhibitor0.6776
P-glycoprotein inhibitor IIInhibitor0.9036
Renal organic cation transporterNon-inhibitor0.7154
CYP450 2C9 substrateNon-substrate0.7919
CYP450 2D6 substrateNon-substrate0.8034
CYP450 3A4 substrateSubstrate0.7504
CYP450 1A2 substrateNon-inhibitor0.5236
CYP450 2C9 inhibitorNon-inhibitor0.7294
CYP450 2D6 inhibitorNon-inhibitor0.7625
CYP450 2C19 inhibitorNon-inhibitor0.5877
CYP450 3A4 inhibitorNon-inhibitor0.6486
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7096
Ames testNon AMES toxic0.5695
CarcinogenicityNon-carcinogens0.8692
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5643 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8956
hERG inhibition (predictor II)Inhibitor0.7228
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral30 mg/1
Tablet, film coatedOral40 mg/1
TabletOral20 mg
TabletOral30 mg
TabletOral40 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6251912 No1998-07-292018-07-29Us
US8426586 No2009-10-102029-10-10Us
US8545884 No2009-12-192029-12-19Us
USRE43431 No2002-01-222022-01-22Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0128 mg/mLALOGPS
logP3.77ALOGPS
logP3.76ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)12.49ChemAxon
pKa (Strongest Basic)8.81ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area88.61 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity131.38 m3·mol-1ChemAxon
Polarizability50.07 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthyridines
Sub ClassQuinazolines
Direct ParentQuinazolinamines
Alternative Parents
Substituents
  • Quinazolinamine
  • N-arylamide
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Saccharide
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Heteroaromatic compound
  • Oxolane
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Secondary amine
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on ke...
Gene Name:
EGFR
Uniprot ID:
P00533
Molecular Weight:
134276.185 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transmembrane signaling receptor activity
Specific Function:
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-...
Gene Name:
ERBB2
Uniprot ID:
P04626
Molecular Weight:
137909.27 Da
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyo...
Gene Name:
ERBB4
Uniprot ID:
Q15303
Molecular Weight:
146806.865 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
Comments
comments powered by Disqus
Drug created on July 17, 2013 15:59 / Updated on December 08, 2016 11:11